FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383551605> ?p ?o ?g. }

• W4383551605 endingPage "11149" @default.
• W4383551605 startingPage "11149" @default.
• W4383551605 abstract "Triple-Negative Breast Cancer (TNBC) is a particularly aggressive subtype among breast cancers (BCs), characterized by anoikis resistance, high invasiveness, and metastatic potential as well as Epithelial–Mesenchymal Transition (EMT) and stemness features. In the last few years, our research focused on the function of MCL1, an antiapoptotic protein frequently deregulated in TNBC. Here, we demonstrate that MCL1 inhibition by A-1210477, a specific BH3-mimetic, promotes anoikis/apoptosis in the MDA-MB-231 cell line, as shown via an increase in proapoptotic markers and caspase activation. Our evidence also shows A-1210477 effects on Focal Adhesions (FAs) impairing the integrin trim and survival signaling pathways, such as FAK, AKT, ERK, NF-κB, and GSK3β-inducing anoikis, thus suggesting a putative role of MCL1 in regulation of FA dynamics. Interestingly, in accordance with these results, we observed a reduction in migratory and invasiveness capabilities as confirmed by a decrease in metalloproteinases (MMPs) levels following A-1210477 treatment. Moreover, MCL1 inhibition promotes a reduction in EMT characteristics as demonstrated by the downregulation of Vimentin, MUC1, DNMT1, and a surprising re-expression of E-Cadherin, suggesting a possible mesenchymal-like phenotype reversion. In addition, we also observed the downregulation of stemness makers such as OCT3/4, SOX2, NANOG, as well as CD133, EpCAM, and CD49f. Our findings support the idea that MCL1 inhibition in MDA-MB-231 could be crucial to reduce anoikis resistance, aggressiveness, and metastatic potential and to minimize EMT and stemness features that distinguish TNBC." @default.
• W4383551605 created "2023-07-08" @default.
• W4383551605 creator A5015443986 @default.
• W4383551605 creator A5031042924 @default.
• W4383551605 creator A5034482702 @default.
• W4383551605 creator A5047869765 @default.
• W4383551605 creator A5053252609 @default.
• W4383551605 creator A5054603398 @default.
• W4383551605 creator A5064996791 @default.
• W4383551605 creator A5068121046 @default.
• W4383551605 creator A5071431506 @default.
• W4383551605 creator A5091875238 @default.
• W4383551605 date "2023-07-06" @default.
• W4383551605 modified "2023-10-14" @default.
• W4383551605 title "MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells" @default.
• W4383551605 cites W1902958101 @default.
• W4383551605 cites W1992095587 @default.
• W4383551605 cites W2028623381 @default.
• W4383551605 cites W2037089102 @default.
• W4383551605 cites W2050173373 @default.
• W4383551605 cites W2050841232 @default.
• W4383551605 cites W2063382533 @default.
• W4383551605 cites W2071121769 @default.
• W4383551605 cites W2075956249 @default.
• W4383551605 cites W2097268515 @default.
• W4383551605 cites W2107277218 @default.
• W4383551605 cites W2113309239 @default.
• W4383551605 cites W2125343707 @default.
• W4383551605 cites W2136828863 @default.
• W4383551605 cites W2138164563 @default.
• W4383551605 cites W2138362890 @default.
• W4383551605 cites W2162647319 @default.
• W4383551605 cites W2192080449 @default.
• W4383551605 cites W2318205119 @default.
• W4383551605 cites W2340021056 @default.
• W4383551605 cites W2509675510 @default.
• W4383551605 cites W2518379431 @default.
• W4383551605 cites W2560367415 @default.
• W4383551605 cites W2593156283 @default.
• W4383551605 cites W2669579916 @default.
• W4383551605 cites W2731626752 @default.
• W4383551605 cites W2770736726 @default.
• W4383551605 cites W2804246302 @default.
• W4383551605 cites W2903756472 @default.
• W4383551605 cites W2911718257 @default.
• W4383551605 cites W2921965589 @default.
• W4383551605 cites W2924663617 @default.
• W4383551605 cites W2938987972 @default.
• W4383551605 cites W2943843209 @default.
• W4383551605 cites W2944754887 @default.
• W4383551605 cites W2945884255 @default.
• W4383551605 cites W2946256330 @default.
• W4383551605 cites W2946572822 @default.
• W4383551605 cites W2946899700 @default.
• W4383551605 cites W2948651503 @default.
• W4383551605 cites W2959179512 @default.
• W4383551605 cites W2962347656 @default.
• W4383551605 cites W2963038261 @default.
• W4383551605 cites W2970952744 @default.
• W4383551605 cites W2974147039 @default.
• W4383551605 cites W2974584278 @default.
• W4383551605 cites W2982619316 @default.
• W4383551605 cites W2993312826 @default.
• W4383551605 cites W2997795468 @default.
• W4383551605 cites W3004733773 @default.
• W4383551605 cites W3015646919 @default.
• W4383551605 cites W3016840787 @default.
• W4383551605 cites W3034520649 @default.
• W4383551605 cites W3038168943 @default.
• W4383551605 cites W3046001009 @default.
• W4383551605 cites W3089752957 @default.
• W4383551605 cites W3107885361 @default.
• W4383551605 cites W3108279690 @default.
• W4383551605 cites W3109741298 @default.
• W4383551605 cites W3111746886 @default.
• W4383551605 cites W3120207869 @default.
• W4383551605 cites W3127564697 @default.
• W4383551605 cites W3127675401 @default.
• W4383551605 cites W3129273166 @default.
• W4383551605 cites W3135258123 @default.
• W4383551605 cites W3153769500 @default.
• W4383551605 cites W3154819335 @default.
• W4383551605 cites W3155531365 @default.
• W4383551605 cites W3159103920 @default.
• W4383551605 cites W3161454284 @default.
• W4383551605 cites W3184968884 @default.
• W4383551605 cites W3197313036 @default.
• W4383551605 cites W3200489044 @default.
• W4383551605 cites W3215942076 @default.
• W4383551605 cites W4205341320 @default.
• W4383551605 cites W4214500057 @default.
• W4383551605 cites W4220698539 @default.
• W4383551605 cites W4220834105 @default.
• W4383551605 cites W4224284036 @default.
• W4383551605 cites W4225454847 @default.
• W4383551605 cites W4229060456 @default.
• W4383551605 cites W4246703595 @default.
• W4383551605 cites W4283388336 @default.

• next